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Focal segmental glomerulosclerosis (FSGS) is a renal pathology finding that represents 
a constellation of rare kidney diseases, which manifest as proteinuria, edema nephrotic 
syndrome, hypertension, and increased risk for kidney failure. Therapeutic options for 
FSGS are reviewed displaying the expected efficacy from 25 to 69% depending on 
specific therapy, patient characteristics, cost, and common side effects. This variability 
in treatment response is likely caused, in part, by the heterogeneity in the etiology and 
active molecular mechanisms of FSGS. Clinical trials in FSGS have been scant in number 
and slow to recruit, which may stem, in part, from reliance on classic clinical trial design 
paradigms. Traditional clinical trial designs based on the “learn and confirm” paradigm 
may not be appropriate for rare diseases, such as FSGS. Future drug development and 
testing will require novel approaches to trial designs that have the capacity to enrich 
study populations and adapt the trial in a planned way to gain efficiencies in trial comple-
tion timelines. A clinical trial simulation is provided that compares a classical and more 
modern design to determine the maximum tolerated dose in FSGS.
Keywords: Fsgs, nephrotic syndrome, therapy, adverse effects, clinical trials
inTrODUcTiOn
Focal segmental glomerulosclerosis (FSGS) manifests with proteinuria, hypertension, and in the 
worse cases progresses to kidney failure. FSGS is a renal pathology finding that represents a constel-
lation of rare kidney diseases and results in a significant public health burden accounting for 5% 
of adults and 12% of children with incident end stage kidney disease (ESKD) in the US annually 
(1). Broadly, FSGS describes a kidney scarring pattern that occurs in a focal and segmental pat-
tern, but does not describe the underlying pathophysiology. FSGS is often classified as primary or 
secondary (e.g., following systemic illnesses IgA nephropathy, post-infectious glomerulonephritis). 
Genetic causes of FSGS may represent a distinct type that does not fit well into this classification. 
In general, the distinction between primary, secondary, and genetic causes of FSGS have classically 
driven therapeutic decision-making and clinical trial design. However, emerging precise molecular 
mechanisms may represent distinct endophenotypes of FSGS, which may also vary temporally by 
disease initiation, maintenance, or progression.
TaBle 2 | common side effects reported with treatment of Fsgs.
Medication common side effects
Corticosteroids Weight gain, hyperglycemia, hypertension, osteopenia, 
mood changes, weakness
Calcineurin inhibitorsa
Cyclosporine Hypertension, gingival hyperplasia, hypertrichosis, infection
Tacrolimus Hypertension, infection, tremor
Mycophenolate Nausea/diarrhea, leukopenia, teratogenic, infection
Cyclophosphamide Nausea, leukopenia, infection, alopecia, teratogenic
ACTH Weight gain, hypertension, rash, acne, hypertrichosis, 
mood changes, weakness
Rituximab Infusion reaction, infection, leucopenia
aCalcineurin inhibitors have an uncommon side effect of nephrotoxicity, which may 
influence clinicians and patients about initial use or duration of therapy.
TaBle 1 | commonly used therapies for Fsgs in 2015.
Proteinuria 
remission (%)
cost (1) Monitoring 
(2)
Corticosteroids 25–59 $ +
Calcineurin inhibitors
 Cyclosporine 46–69 $$$ ++
 Tacrolimus a $$$ ++
Mycophenolate 33 $$ ++
Cyclophosphamide 27–55b $ +++
ACTH 29a $$$$$ +
Rituximab 38b $$$$ +
(1) Cost comparison of these agents is based on a course of therapy, with monthly 
costs ranging from the approximately $30 ($) to $46,000 ($$$$$).
(2) Monitoring frequency is labeled for frequency to screen for side effects, drug level, 
and therapeutic effects. Increasing number of + are used to show increasing frequency 
of standard lab monitoring.
aThe expected response to calcineurin inhibitors is approximately the same. 
Publications that have compared the two show similar efficacy but a worse adverse 
event profile with cyclosporine.
bResults are reported from steroid resistant and steroid sensitive patients.
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Despite the significant patient and health burden, there is a 
paucity of therapeutic options for those with FSGS. Therapies 
available include immunosuppression, renin–angiotensin– 
aldosterone blockade, lipid lowering agents, and other blood 
pressure lowering agents as necessary. Unfortunately, the avail-
able immunosuppression therapies have a significant toxicity 
profile that may be dose limiting. Side effects, such as those 
altering physical appearance (e.g., alopecia, hirsutism, and weight 
gain) or physical function (e.g., weakness, tremor, and infertility), 
may contribute to poor adherence. These decisions are further 
complicated by those with monogenetic forms of FSGS, who may 
respond to immunosuppression therapy, but at very low rates (2).
A number of underlying biological mechanisms, multiple 
causes of FSGS, and side effect profiles contribute to the present 
day challenge of identifying effective and acceptable treatments. 
Globally, research teams are seeking a better understanding of 
the underlying biological mechanisms of subgroups of patients 
with FSGS that may provide targets for future therapy (3). This 
paper will provide a summary of commonly used therapies for 
FSGS and present strategies for successful clinical trial design to 
support the testing of novel agents.
cUrrenT TheraPies FOr Fsgs
A majority of therapies for FSGS (Table 1) have been either tested 
in phase 2 trials, but not used for registration (product labeling) or 
utilized without significant evidence as a treatment of last resort 
(3–7). The published estimates of efficacy vary widely from 25 to 
69% across agents. Recent evidence supports that certain patient 
populations have a lower likelihood of responding to therapy. 
For instance, individuals with high risk APOL1 genotypes, found 
in individuals of African ancestry, have a higher likelihood of 
unfavorable outcomes (continued proteinuria, ESKD) (8–11). 
Furthermore, efficacy may also be predicted by response to prior 
therapy, such as glucocorticoids. Differences in such patient 
characteristics have important implications in study interpreta-
tion and trial design.
The initial selection of an appropriate therapeutic regimen by 
the treating physician is related to the anticipated likelihood of 
disease control (proteinuria resolution, preservation of kidney 
function) and the safety profile of the therapeutic agent. In 
the absence of more precise biomarkers, the subsequent tailor-
ing of therapeutic regimens for patients are driven by disease 
characteristics (treatment response), side effect profile, or 
cost/convenience factors. Table  2 summarizes the common 
side effects that may influence differential treatment selection.
cUrrenT clinical Trial Designs  
anD sTaTisTical cOnsiDeraTiOns 
FOr rare Diseases
Since the Orphan Drug Act was passed in 1983, an increased 
number of drugs and biologics have been approved for rare dis-
eases in the US (12). An orphan drug is defined as one targeted 
toward rare diseases (prevalence <200,000 persons) or disease 
with greater prevalence but for which the cost of drug develop-
ment is expected to not be recoverable from US sales (13). In 
Europe, rare diseases are defined as life-threatening or chroni-
cally debilitating conditions that affect ≤5 in 10,000 people in 
the EU (Official Journal of the European Union 2009/C 151/02).
Although there is an ethical imperative to hold clinical tri-
als in rare diseases to rigorous ethical and scientific standards, 
analyses of rare vs. non-rare clinical trials indicate that there are 
differences in design characteristics. Trials in orphan drugs are 
more likely to be smaller, non-randomized, lack blinding, and 
use disease response instead of progression or survival endpoints 
(14–16).
changing The ParaDigM
The utilization of traditional clinical trial designs may not be 
appropriate for rare diseases. Fortunately, a myriad of design 
and analysis options (see Table  3) exist in the clinical trials 
and statistical literature that allow for the study of drugs in rare 
diseases, such as FSGS, that meet stringent effectiveness and 
safety standards. A clinical trial development program of studies 
in FSGS should result in evidence that provides confidence for 
TaBle 3 | Brief glossary of clinical trials terms.
Term Brief description
3 + 3 trial design A conventional and popular phase 1 dose escalation design that estimates the MTDa by sequentially studying cohorts of size 3
Adaptive design A clinical study design that uses accumulating data to decide how to modify aspects of the study as it continues, without 
undermining the validity and integrity of the trial (17)
Bayesian methods Bayesian methods use prior information on the differences between treatments before the trial is completed, and update this 
information based on data obtained from the trial. The difference between treatments is not a single fixed parameter in the Bayesian 
approach; rather, a distribution of potential values characterizes treatment differences
Continual reassessment  
method (CRM)
CRM is an adaptive dose-finding study design that uses Bayesian methods to estimate the MTD. It frequently results in fewer 
adverse events and more accurately estimates the MTD
Crossover design A clinical trial design in which participants receive a sequence of different treatments, resulting in within-subject comparisons that 
generally reduced the required sample size. This design is in contrast to the parallel-group design where participants receive only  
one protocol-specified treatment
Dose limiting toxicity (DLT) Severe but (ideally) reversible adverse events that occur within a generally short protocol-defined period
Frequentist methods A framework of statistical inference that is generally taught in most introductory statistical courses, that treats the difference between 
treatments as an unknown and fixed parameter. Clinical trial results are considered from the perspective of multiple independent 
repetitions of the experiment which sometimes cause difficulties in the interpretation of results
“Learn and confirm” clinical trial 
paradigm
An alternative to the traditional “phased” approach to drug development (i.e., phase 1, 2, and 3). The goal of the learning phase is 
to assess the relationship between the dose and administration of a new drug and its expected efficacy and safety. The goal of the 
confirming phase is to capitalize on the more complete information obtained in the learning phase to efficiently study the risk-benefit 
of the new agent
Maximum tolerated dose (MTD) The highest dose of a drug or treatment that does not cause unacceptable side effects (18)
N-of-1 design Single-subject clinical trial that has the goal of determining the best intervention for an individual patient based on objective criteria
Seamless trial designs Clinical trial designs that address, within a single trial, objectives that are normally achieved through separate trials
MTD, maximum tolerated dose.
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patients, regulators, investigators, and clinicians, given the cur-
rent therapeutic options and knowledge base.
Classical drug development employs a “learn and confirm” 
paradigm over a series of steps. The drug development pipeline 
begins with discovery with preclinical in vitro and in vivo animal 
experiments and toxicology studies. Phase 1, phase 2, and proof-
of-concept studies in human participants follow in the explora-
tory phase, with (generally) two adequate and well-controlled 
phase 3 studies conducted in the full development confirmatory 
phase. After approval, post-marketing phase 4 studies are often 
conducted to provide additional characterization of the efficacy 
and safety in a broader patient population. Generally, each step 
involves a separate study during the human studies stage.
This classical drug development process is often not feasible 
in rare diseases. In this setting multistage designs, particularly 
adaptive designs, and seamless phase 1/2 or phase 2/3 trials may 
be used to maximize information while minimizing the strain 
on the available patient population [based on Orloff et al. (61)]
(Figure 1). Adaptive designs refer to studies that include “a pro-
spectively planned opportunity to modify one or more specified 
aspects of the study design and hypotheses based on analysis of 
study data (usually interim data)” (19). Adaptive trials have been 
a recent topic in the clinical trials literature, with seminal papers 
in 2006 (17, 20–22); however, the concept has been around since 
the 1970s in medical trials with adaptive randomization and 
sequential designs (23). In addition, Bayesian methods offer an 
alternative statistical approach to inference (relative to the fre-
quentist or classical approach) that treats probability as a measure 
of the degree of personal belief instead of the frequency achieved 
in long-run repetitions of an experiment. Bayesian methods have 
gained acceptance since the early 2000s, with use of the phase 
1 continual reassessment method (CRM; Bayesian in everything 
but name) (24), and Bayesian stopping rules in phase 2 trials (25). 
The literature on trial design in rare diseases or small sample 
size situations is redolent with suggestions for use of Bayesian 
methods (26–29).
These novel designs have been successfully used in a variety of 
therapeutic areas, including rare and common diseases. A modifi-
cation of the time-to-event CRM approach (TITE-CRM) was used 
in a phase 1 study of continuous MKC-1 in patients with advanced 
or metastatic solid malignancies (30). The study identified a 
maximum tolerated dose by studying 24 patients, and concluded 
that the adaptive Bayesian design allowed for a more efficient dose 
escalation and also allowed for late toxicities. Kaufmann et al. (31) 
designed a multicenter adaptive two-stage phase 2 trial of CoQ10 
in amyotrophic lateral sclerosis (ALS) to identify an appropriate 
dose in stage 1 and then compare the selected dose against placebo 
for futility in stage 2. They concluded their adaptive design avoided 
the need for a much larger conventional phase 3 trial. Finally, 
an adaptive seamless phase 2/3 randomized trial of dulaglutide 
combined with metformin in type 2 diabetes patients efficiently 
(32) explored a large number of doses and selected two doses for 
head-to-head comparison with sitagliptin; both dulaglutide doses 
demonstrated superior glycemic control (33).
study Population
A common approach to the testing of novel agents for FSGS or 
other conditions will select a patient sample that has demonstrated 
Conventional Phases of 
Drug Development Preclinical Testing Phase 1 Phase 2 Phase 3
Goals Assess safety & biological activity Determine safety & dose
Evaluate 
activity & side 
effects
Confirm efficacy 
& monitor 
(longer-term) 
safety
More Recent Model of 
Drug Development Target discovery and validation Phase 1/2 Phase 2/3 
Goals
Provide data to construct models; 
establish correlation between 
biomarkers and clinical endpoints
Determine proof-of-
concept and establish 
dose selection
Confirm optimal dose, 
dosing regimen and 
esablish risk/benefit ratio
FigUre 1 | Models of drug development.
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resistance to standard therapies, positioning the novel agent as a 
salvage therapy. Depending on the investigational drug target, 
this approach may doom the agent to failure as the patients 
on study may have already entered a late or irreversible phase 
of the disease. FSGS targeted therapies may be best suited to 
patients in early or mid-disease where the potential for the drug 
to demonstrate activity against a molecular target can be shown. 
Enrichment designs represent a unique opportunity in FSGS 
by selecting patients who are more likely to respond to therapy, 
based on specific biomarkers. Such designs reduce sample size 
by reducing patient heterogeneity, improving the chance of suc-
cessful enrollment. The development of biomarkers and targeted 
agents targeted agents in earlier phases of drug development in 
FSGS should help in assessing whether this strategy would be 
advantageous in later confirmatory stages (34).
Finally, FSGS affects patients of all ages. As the implications 
of uncontrolled FSGS resulting in kidney failure are similar 
across the lifespan, drug development strategies should include 
children in every setting where drug safety has not shown specific 
additional risk in immature preclinical testing.
endpoints
The goal of FSGS therapies is the normalization of urinary protein 
excretion [measured urine protein/creatinine ratio (UP/C)], 
preservation of kidney function (3), restoration of the patient 
health, and avoidance of adverse events (3). Efficacy endpoints 
currently being used in many FSGS trials include the proportion 
of participants who achieve complete remission (UP/C <0.3 g/g 
and preserved kidney function) and partial remission (50% UP/C 
reduction and <3 g/g and preserved kidney function). These end-
points have been justified based on two retrospective observational 
studies demonstrating the relationship between remission status 
and long-term renal survival (35, 36). The timing for achieving 
remission is generally assessed at 3–6 months after initiation of 
study medication. Characterizing response as a binary outcome 
generally leads to larger sample sizes (37). Smaller clinical trials 
may be achievable in the confirmatory stages of development in 
FSGS, for similar Type I and Type II error rates, if UP/C is ana-
lyzed as a continuous outcome. For example, multiple measures 
of UP/C can be collected with analyses based on longitudinal 
methods [see, for example, the approach of Greene et  al. (38) 
for eGFR endpoints]. Research is needed to better understand 
the differences in UP/C that are clinically meaningful and would 
result in changes in clinical practice.
learning and confirmatory Phase goals 
and general considerations
During the learning phase of drug development in FSGS, we 
investigate the correct dose range by investigating preliminary 
efficacy and ensuring that the drug meets minimal requirements 
for dose-limiting toxicity and tolerance. In the confirmatory phase, 
the goal is to obtain sufficient efficacy and safety information in 
well-controlled trials to support its acceptance. The control group 
may be placebo (superiority trials) or an active control (superior-
ity, non-inferiority, or equivalence trials). The highest levels of 
medical evidence are achieved through the use of randomization, 
blinding, and concurrent controls, and there should be strong 
rationale for not using these features in FSGS trials.
Crossover designs and N-of-1 trials have been suggested for 
rare diseases (27) because they reduce sample size by allowing 
for within-subject treatment comparisons. In FSGS confirmatory 
trials, where the endpoints may be measured at 6 months or later, 
5Spino et al. New Paradigm for Trials in FSGS
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there are design implications of period effects where the disease 
is not stable over the time course of the two treatment periods.
The impact of design and analysis decisions should be fully 
evaluated. Frequentists calculate sample size based on the hypoth-
esis testing framework that specifies the type I error, power, and 
expected treatment difference. The Bayesian approach does not 
employ a strict need to calculate sample size because the goal is 
to update prior beliefs about the null hypothesis with the data. In 
past FSGS trials, the traditional, equal-allocation, fixed sample-
size design was most commonly used. Clinical trials simulations 
can be used for future trials to assess the tradeoffs between 
frequentist and Bayesian options, assessing characteristics of the 
design for specific agents and phases, such as probability of stop-
ping for futility incorrectly and sample size options to achieve a 
certain decision criterion.
adaptive Designs
An adaptive design is defined as “a clinical study design that uses 
accumulating data to decide how to modify aspects of the study 
as it continues, without undermining the validity and integrity 
of the trial” (17). An adaptive design requires access to accumu-
lating data at multiple stages of the trial (20). Adaptation rules 
applied at each interim analysis may affect: how a subject will be 
allocated to the available arms of the trial, how many subjects will 
be sampled at the next stage, when to stop the trial for efficacy, 
harm or futility, and other decision features of the trial (20). An 
important prerequisite for an adaptive trial is that the accumulat-
ing information on the end point can be assessed quickly enough 
to trigger the adaptive decisions relative to the enrollment rate. 
FSGS trials typically meet this criterion because the prevalence 
of the disease results in slow enrollment and normalization of 
urine protein excretion can be observed as early as 2–3 months 
depending on the agent under investigation.
In early phases of FSGS development, the following adaptive 
approaches may be most useful:
 ⚬ Adaptive dose finding is used in early phase clinical develop-
ment to identify the minimum effective dose and/or the maxi-
mum tolerable dose, which is used to determine the dose level 
for the next phase clinical trials. In particular, the continual 
re-assessment method allows assessment of dose-limiting 
toxicity in small cohorts at a given dose (one to four patients 
commonly), updating the dose-toxicity curve, and treating 
additional cohorts until a pre-specified level of certainty is 
achieved (39).
 ⚬ Drop-the-loser or play-the-winner design allows for dropping 
an inferior treatment group or maintaining a superior treat-
ment group. A drop-the-losers design also allows adding 
additional arms. These designs would be useful in FSGS when 
there are uncertainties regarding the dose levels for a new 
agent. These two approaches can be considered types of adap-
tive randomization methods, where the probability of being 
assigned to a dropped arm is 0 (see below).
 ⚬ Adaptive seamless 1/2 trial designs address within a single trial 
objectives that are normally achieved through separate trials 
in phase 1 and phase 2 of clinical development.
Adaptive designs that may be more useful during later stage 
drug development in FSGS include
 ⚬ Sequential designs allow for prematurely stopping a trial due to 
safety, futility, or efficacy (benefit) with options of additional 
adaptations based on results of interim analysis. Types of 
sequential designs include group sequential designs that employ 
repeated significance testing at pre-specified interim analysis 
times and boundaries approach where the amount of informa-
tion and treatment effect size are assessed multiple times during 
the study (40–42). With these designs, the final sample size is 
unknown at the trial initiation, but sample sizes are generally 
smaller than a classical fixed sample size approach (40).
 ⚬ Sample size re-estimation design allows for sample size adjust-
ment based on interim analyses. When limited information is 
available a priori on the variance of the outcome (e.g., variance 
of change from baseline to month 3 in UP/C) or the estimated 
treatment effect (e.g., proportion of participants who achieve 
complete remission), sample size re-estimation is attractive. 
A common method is to calculate the conditional power that 
a treatment difference will be observed at the end of the trial, 
given the current information. Hybrid methods are often used 
where the trial may continue with the original sample size if 
the conditional power if sufficient, may be stopped for futility 
if the increase is sample size is too great, or may be enlarged if 
neither of the other conditions is met (43).
 ⚬ Adaptive randomization design allows modification of rand-
omization schedules based on varied or unequal probabilities 
of treatment. It is a type of allocation rule that determines how 
new patients are assigned to treatments dynamically (20). One 
such type of adaptive randomization is response-adaptive ran-
domization where the allocation probabilities are unbalanced 
to provide a greater likelihood that treatments having more 
favorable outcomes are assigned.
 ⚬ Adaptive seamless 2/3 trial design addresses within single trial 
objectives that are normally achieved through separate trials 
in phase 2b and phase 3 of clinical development.
Bayesian Methods
The difference between treatments is assumed to be an unknown 
and fixed parameter in the frequentist framework, whereas 
the treatment difference is not a single fixed parameter in the 
Bayesian approach. It is characterized by a distribution of poten-
tial values (26, 44). Bayesian methods use prior information on 
the differences between treatments before the trial is completed, 
and update this information based on data obtained from the trial 
producing a posterior distribution that can then subsequently be 
used as the prior for the next interim analysis or stage of a trial. 
This approach is attractive in the context of seamless phase 1/2 
and phase 2/3 trials where smooth transitions between stages 
can occur as we learn more about treatment differences as the 
data accumulate (45, 46). However, there are many examples 
of adaptive designs that use both Bayesian (47) and frequentist 
approaches (47–49).
A key stumbling block in Bayesian methods is elicitation of the 
prior distribution of the treatment difference and the degree of 
6Spino et al. New Paradigm for Trials in FSGS
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certainty and subjectivity (27). Information on the prior distribu-
tion for the unknown treatment effect can be determined from 
data from the literature (e.g., a single drug approved for another 
indication, characteristics for a class of similar agents) or from 
expert knowledge (28). The biases that may result from expert 
opinion have been widely discussed and heuristics have been 
developed to minimize these biases (50–52). Hampson et al. (28) 
provide an example of elicitation of priors for a clinical trial in 
very rare diseases. Interestingly, the eliciting of prior beliefs may 
provide benefits for frequentist clinical trials in considering the 
magnitude of effect for determining sample size and assessing the 
level of evidence needed to convince the clinical community to 
change practice (53).
Both the use of adaptive design methods and the Bayesian 
approach in clinical trials is consistent with the FDA’s Clinical 
Path Initiative (54) that was originally developed to deal with the 
problem of increased trial spending without a resulting increase 
in the success rate of new drug approvals. The FDA advocated for 
advancing innovative trial designs, capitalizing on use of prior 
experience, or accumulating information in a trial. Dr. Woodcock, 
then Acting Deputy Commissioner for Operations at the FDA, 
emphasized two points: (1) there should be scientific evidence 
that a drug or biological works and (2) there should be a degree 
of certainty about the prediction that the new product works. 
She notes that the law does not tell us exactly what the degree 
of certainty should be, but a level of evidence from the current 
development that depends somewhat upon the prior knowledge 
base – whether mechanistic or more general. Thus, the extension 
of these ideas from common diseases to rarer diseases, such as 
FSGS, seems a natural step in clinical trials methodology. As with 
conventional clinical trials designs, the new proposed paradigms 
do not compromise the ethical imperative to protect human 
subjects according to such guidelines as the Belmont Report and 
the Declaration of Helsinki.
eXaMPle
One context where using adaptive and Bayesian methods in clini-
cal trials can benefit advances in FSGS therapies is in dose-finding 
trials. The methods that are used for dose-finding trials in non-
rare diseases could be costly and imprecise. We can reduce the 
sample size needed for estimating the maximum tolerated dose 
while maintaining precision by using the CRM first presented by 
O’Quigley et al. (55). We compare the most common method for 
dose-finding clinical trials (the 3 + 3 design) to the CRM using 
simulations run under reasonable settings for FSGS.
The two main goals of dose-finding clinical trials are to put 
as many subjects as possible in the dose closest to the maximum 
tolerated dose (MTD) and to estimate the MTD as accurately as 
possible. The MTD is defined by the National Cancer Institute 
as “the highest dose of a drug or treatment that does not cause 
unacceptable side effects” (18). Unacceptable side effects are 
determined by the proportion of subjects in the population who 
would have a dose limiting toxicity (DLT). In our FSGS example, 
we consider a >30% decrease in eGFR to identify a DLT and 30% 
of the study population having DLTs at a dose defines the MTD. 
Generally, to obtain the best estimates of the dose–response 
relationship, we would want to allocate patients equally to all 
doses to gain as much information as possible. However, this is 
contrary to the goal of treating as many patients with the cur-
rently estimated MTD. Therefore, we compare the 3 + 3 and CRM 
methods on how often each selects the correct MTD dose and 
how many subjects are allocated to the MTD dose to evaluate the 
ability of these methods to meet both goals simultaneously.
Methods
As described by Storer (56), the 3 + 3 method assigns the first 
three subjects in the lowest dose group. If no subjects have a DLT, 
then the next three subjects receive the next highest dose. If one 
subject out of the original three has a DLT, then the next three 
subjects are allocated to the same dose. If two or more subjects 
have DLTs, then the trial is stopped and the MTD is selected to 
be the next lowest dose. If the first dose has more than one DLT, 
then it is selected as the MTD. Because many drugs assessed in 
FSGS trials have been developed for other indications, we limit 
the number of doses studied to four in this example; thus, the 
maximum sample size is 24 with the 3 + 3 design.
The CRM is an adaptive and Bayesian method for dose-finding 
trials in which we use prior information combined with collected 
data to help find the MTD (Bayesian) and give future subjects 
doses based on estimates from collected and prior information 
(adaptive). After each subject is enrolled and treated, the outcome 
information is combined with prior information and previous 
outcomes to update the dose–response curve from which the 
MTD is estimated and given to the next subject. The sample size 
in CRM can be fixed or variable. To provide a fairer comparison 
with the 3 + 3 design, we used an early stopping rule to select 
the estimated MTD as the dose which is assigned seven times in 
the trial (which limits the maximum sample size to 24). Stopping 
rules of this kind were first used by Korn et al. (57) and further 
discussed by O’Quigley (58).
For both 3 + 3 and CRM designs, we ran 10,000 trial simula-
tions for four different true DLT probability scenarios. For each 
scenario, we compared the proportions of dose selected, the pro-
portion of doses assigned, and the average and SD of sample sizes 
for both designs. We chose to always include the MTD of interest 
as one of the doses in our simulations for ease of comparison of 
trial types. The simulations were run using R and the package 
dfcrm created by Cheung (59, 60).
results
In Scenario 1, the CRM selects the correct dose about 62% of 
time where the 3 + 3 design identifies the MTD just under 35% 
of the time (Table 4). The 3 + 3 design also chooses dose 1 in this 
scenario 50% of time, meaning that half of the time we would 
expect the 3 +  3 to identify the estimated MTD to be a dose 
where no DLTs would happen. There are two doses in Scenario 
2 in which the true DLT proportion is 30%, which are identified 
by the CRM 72% of the time and by the 3 + 3 design <50% of the 
time. Scenario 3 and Scenario 4 show the CRM is doing a better 
job at selecting the correct dose by approximately 10% over the 
3 + 3 design. In Scenario 4, the 3 + 3 design again selects a dose 
as the estimated MTD where no DLTs would occur nearly 40% 
of the time.
TaBle 5 | Mean (sD) sample size by design in 10,000 simulated trials.
Dose scenario Design
3 + 3 crM
Scenario 1: (0.00, 0.30, 0.40, 0.60) 10.1 (3.2) 12.0 (1.7)
Scenario 2: (0.05, 0.05, 0.30, 0.30) 13.3 (3.5) 11.8 (2.0)
Scenario 3: (0.05, 0.10, 0.15, 0.30) 14.4 (3.7) 11.9 (2.2)
Scenario 4: (0.00, 0.25, 0.30, 0.45) 11.3 (3.7) 12.1 (1.7)
TaBle 4 | Percentage of time true DlT dose is selected by design in 
10,000 simulated trials.
Dose scenario Design Dose
1 2 3 4
Scenario 1: (0.00, 0.30, 0.40, 0.60) 3 + 3 50.3 34.6 14.6 0.6
CRM 10.9 62.2 24.1 2.8
Scenario 2: (0.05, 0.05, 0.30, 0.30) 3 + 3 5.0 48.6 26.5 19.9
CRM 6.1 21.5 46.7 25.7
Scenario 3: (0.05, 0.10, 0.15, 0.30) 3 + 3 11.7 16.5 41.3 30.5
CRM 7.1 12.9 37.6 42.4
Scenario 4: (0.00, 0.25, 0.30, 0.45) 3 + 3 39.7 30.6 25.0 4.6
CRM 5.9 47.8 33.9 12.4
The bolded value is the true DLT dose.
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The CRM tends to have about 12 subjects needed for the trial 
with SDs around 2 for all scenarios investigated (Table 5). On the 
other hand, the 3 + 3 design shows greater fluctuations in mean 
sample size (10.1–14.4) with larger SDs (approximately 3.5 for 
each simulation) than the CRM designs.
Our small simulation study shows the advantages of a Bayesian 
adaptive approach (CRM) over a more traditional clinical trial 
dose-finding design (3 + 3) in terms of assigning as many patients 
to the MTD as possible and selecting the correct MTD. In the 
long term, using the CRM over the 3 + 3 design could lead to 
enormous financial and time savings by increasing the probability 
that we move to further phases of clinical trials with the correct 
dose. Although there is no clear winner between the trial types 
for sample size under all scenarios investigated (Table  5), the 
stability of the average sample size and smaller SD when using the 
CRM would allow investigators to be more confident in expected 
sample size needed in the planning stages of the trial. Using the 
CRM may also decrease the concern of running a trial which uses 
a sample size closer to the maximum number of 24 subjects.
cOnclUsiOn
Focal segmental glomerulosclerosis therapies are challenging 
based on incomplete efficacy and safety information, leading to 
the inability to define the right agent for the right patient. Novel 
agents that are based on molecular profiling are emerging which 
will benefit from an enriched trial eligibility approach. While 
enrichment may improve signal, trials will need to be designed 
for feasibility in FSGS endophenotypes defined by molecular 
profiling and target-relevant biomarkers. Rational application of 
more modern clinical trials designs, that have found increasing 
acceptance in the pharmaceutical, regulatory, and academic envi-
ronments, increases the chance of successful studies that evidence 
of safe and effective therapies in rare diseases, such as FSGS.
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